BioLife Solutions (BLFS) Stock Overview
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BLFS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
BioLife Solutions, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.73 |
| 52 Week High | US$29.55 |
| 52 Week Low | US$19.10 |
| Beta | 1.95 |
| 1 Month Change | 6.74% |
| 3 Month Change | 33.13% |
| 1 Year Change | 19.84% |
| 3 Year Change | 48.85% |
| 5 Year Change | -2.97% |
| Change since IPO | -94.89% |
Recent News & Updates
BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)
Oct 01BioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce
Sep 06
Recent updates
BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)
Oct 01BioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce
Sep 06Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
Aug 09Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)
Jul 04
Expanding Cell And Gene Therapy Workflows Will Shape Future Opportunities
Market leadership in cell and gene therapy, combined with expanded high-value product offerings, drives strong revenue and margin growth opportunities.An Intrinsic Calculation For BioLife Solutions, Inc. (NASDAQ:BLFS) Suggests It's 44% Undervalued
Apr 30With BioLife Solutions, Inc. (NASDAQ:BLFS) It Looks Like You'll Get What You Pay For
Apr 03Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Jan 24BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
Dec 15Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
Nov 30Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
Nov 15Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Oct 25Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Sep 14Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
Aug 30Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
Aug 14BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Jun 20A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Jun 05Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
May 14Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
May 13Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
May 11Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Shareholder Returns
| BLFS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.0% | 1.4% | -1.5% |
| 1Y | 19.8% | -12.4% | 14.4% |
Return vs Industry: BLFS exceeded the US Life Sciences industry which returned -13.5% over the past year.
Return vs Market: BLFS exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| BLFS volatility | |
|---|---|
| BLFS Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BLFS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BLFS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 159 | Rod de Greef | www.biolifesolutions.com |
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions, Inc. Fundamentals Summary
| BLFS fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$18.91m |
| Revenue (TTM) | US$93.47m |
Is BLFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLFS income statement (TTM) | |
|---|---|
| Revenue | US$93.47m |
| Cost of Revenue | US$33.03m |
| Gross Profit | US$60.44m |
| Other Expenses | US$79.36m |
| Earnings | -US$18.91m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 64.67% |
| Net Profit Margin | -20.24% |
| Debt/Equity Ratio | 2.9% |
How did BLFS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 18:17 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioLife Solutions, Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| George Zavoico | B. Riley Securities, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |